AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02007928 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rispéridone, aripiprazole, olanzapine
Description: Study:~We propose a prospective, interventional multicenter study.~Method:~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug.
Study NCT02888028 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICD remote monitoring
Description: ICD remote monitoring additionally to regular in-office visits
Study NCT02888028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
Study NCT01166594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intrableb injection
Study NCT01166594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: intrableb BSS injection
Study NCT03755024 — intervention group
Intervention type: DEVICE
Intervention: ultrasound
Description: The compulsory ultrasound measurements to be obtained at all visits include the following biometrical parameters:~* Biparietal diameter~* Head circumference~* Abdominal circumference~* Femur length~* Humerus length
Study NCT01400841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HAART 300 Annuloplasty Device
Description: Implantation of device for aortic valve repair
Study NCT03930316 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NOX T3
Description: portable sleep study device
Study NCT02726763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Study NCT02726763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Study NCT02896127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Induction: 4x 150 mg Secukinumab s.c. weekly~Maintenance: 150 mg Secukinumab s.c. monthly~All Subjects received blinded treatment weekly starting at baseline, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4 until Week 16. At Week 16, Group 1 patients continued using secukinumab 150 mg and Group 2 patients started receiving secukinumab 150 mg dosing every four weeks. Treatment was provided open-label from Week 16 onward, as all patients took 150 mg s.c. every 4 weeks; however, subjects, investigators, and site staff remained blinded to initial randomized group assignment.
Study NCT02896127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
Study NCT02753712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/Formoterol BAI
Study NCT02753712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)
Study NCT04138927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib disodium
Description: Fostamatinib is supplied in two (2) dosage strengths: 100 mg and 150 mg.
Study NCT03465293 — intervention group
Intervention type: OTHER
Intervention: Bacterial composition and activity after bowel preparation
Description: Bacterial composition and activity and patient's symptoms will be assessed pre and post bowel preparation taken as part of the preparation to have a pre-planned colonoscopy
Study NCT02886585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02886585 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT02886585 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT
Study NCT02886585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Study NCT01550939 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Ophthalmic Biometer
Description: One complete biometry examination
Study NCT04622254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study NCT04622254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
Study NCT04622254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
Study NCT01023659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion
Description: bupropion, 150 mg twice daily plus weekly motivational emails for 12 weeks
Study NCT01023659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: varenicline, 1 mg twice daily plus weekly motivational emails for 12 weeks
Study NCT01023659 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motivational emails
Description: brief motivational emails, sent weekly for 12 weeks
Study NCT02744846 — intervention group
Intervention type: DRUG
Intervention: Antibiotics exposure
Study NCT02057757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Participants 1 to 3 years old: 5 mL oral suspension (100 mg NTZ) every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL oral suspension (200 mg NTZ) every 12 hours for 5 days.~Participants 12 years and older: two 300-mg NTZ tablets orally twice daily for 5 days.
Study NCT02057757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants 1 to 3 years old: 5 mL placebo oral suspension every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL placebo oral suspension every 12 hours for 5 days.~Participants 12 years and older: two placebo tablets orally twice daily for 5 days.
Study NCT02575781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR428926
Description: Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
Study NCT01997086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transforaminal endoscopic discectomy (PTED)
Description: Percutaneous transforaminal endoscopic discectomy
Study NCT01997086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microendoscopic discectomy (MED)
Description: Microendoscopic discectomy
Study NCT00066196 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI--522
Description: IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL.
Study NCT00066196 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Integrin + Dacarbazine
Description: supplied in other formulations
Study NCT03614793 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cooled Radiofrequency Ablation of Medial Branch Nerves versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome
Description: Radio frequency ablation (RFA) is a medical procedure in which heat is generated from high frequency electrical current in order to lesion (burn) nervous tissue.
Study NCT03541733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mid-gut tubing
Description: mid-gut tubing at different time
Study NCT02568488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850 mg orally twice daily for 6 months
Study NCT01123538 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Progesterone
Description: 200 mg/day oral micronized natural progesterone (e.g. Utrogestan® 100mg) + 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg) during a year
Study NCT01123538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlormadinone acetate
Description: 5 mg/day oral chlormadinone acetate (e.g. Luteran® 5mg)+ 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg)
Study NCT00895219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing re-training
Description: Breathing re-training
Study NCT00895219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing re-training and musculoskeletal techniques
Description: Breathing re-training and musculoskeletal physiotherapy techniques including mobilisation techniques to normalise muscle and joint restrictions, doming of the diaphragm to enhance contraction and relaxation, and rib raising to free restriction in rib cage motion.
Study NCT00393172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: 5 days per week exercise for 4 months
Study NCT02538497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Newborn Behavioral Observation (NBO)
Description: The Newborn Behavioral Observation (NBO) is a flexible parental guidance methodology which takes between 20 and 40 minutes to administer. It consists of 18 neurobehavioral observations which give a profile of the infant´s behavioral repertoire along the dimensions: attentional-interactional, autonomic, motor and state organization.~The intervention group will receive 3 NBO consultations: 1) Routine care plus the NBO at the hospital within two days post-delivery; 2) Routine home visit plus the NBO by a public health nurse when the infant is 7-10 days old; and 3) NBO at the well-baby clinic when the infant is about 4 weeks old.
Study NCT02538497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine care
Description: The control group will receive routine care. Between 7 and 10 days after birth a public health nurse routinely visits the family at home. Six weeks after birth, the mother and the infant visit the well-baby clinic
Study NCT02538497 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine care
Description: The control group will receive routine care. Between 7 and 10 days after birth a public health nurse routinely visits the family at home. Six weeks after birth, the mother and the infant visit the well-baby clinic
Study NCT03162250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC
Description: Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.
Study NCT04274933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral
Study NCT04274933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Tablet; Oral
Study NCT01862978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Study NCT01862978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparin
Study NCT01862978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin
Study NCT01862978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nadroparin
Study NCT01862978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04485481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-914
Description: Single dose from 0.1mg/kg to TBD
Study NCT04485481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching single dose placebo
Study NCT04485481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-914
Description: Multiple dose from TBD to TBD
Study NCT02845037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).
Study NCT04485481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching multiple dose placebo
Study NCT01465802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent
Study NCT01465802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Dacomitinib 45 mg orally daily on a continuous schedule for the first 10 days in Cycle 1, followed by 4 days off treatment, followed by continuous daily dosing until disease progression, toxicity, death or withdrawal of consent
Study NCT01465802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline or Doxycycline placebo BID for 4 weeks
Study NCT01465802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)
Study NCT01465802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alclometasone cream
Description: Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks
Study NCT02321579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin B-6
Description: 50 mg/d
Study NCT02321579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: 500 mg/d
Study NCT02321579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrins
Description: 50 mg/d
Study NCT04400305 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Digital Health Online Platform
Description: The website has 10 lessons that the participant will gain access to on a bi-weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity
Study NCT00323739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab 10mg/kg, IV infusion, every 2 weeks
Study NCT00323739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 10 mg by mouth daily
Study NCT03879681 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jelly confectionary Snakes
Description: The participants will be randomized by computer generated randomisation to receive either the jelly snake (n=120) or no intervention (n=120) apart from standard institutional management.~All children randomised into the snake group will be offered a chewy jelly snake once alert and cooperative in PACU or on the ward once University of Michigan Sedation Scale (UMSS) is 025,26. The UMSS is a simple observational tool that assesses the level of alertness on a five-point scale ranging from 1 (wide awake) to 5 (unarousable with deep stimulation).~The children randomized into the control group will receive a chewy jelly snake as a treat at discharge.
Study NCT00838305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA and citalopram
Description: MDMA 1.5 mg/kg and citalopram 20 mg
Study NCT00838305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
Study NCT04314193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral methotrexate (15 mg weekly to be increased to 25 mg weekly) for 24 weeks.
Study NCT04314193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral prednisolone (start 40 mg daily, to be tapered to 10 mg daily) for 24 weeks.
Study NCT03037151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazaoprevir/Elbasavir
Description: treatment naive
Study NCT03037151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazaoprevir/Elbasavir/RBV
Description: treatment experienced
Study NCT05702333 — intervention group
Intervention type: DRUG
Intervention: Epinephrine Norepinephrine Dobutamine Dopamine Levosimendan
Description: Vasoactive-inotropic drugs were administered according to clinical decision of the doctor in charge.
Study NCT04317664 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: In-vehicle device
Description: The Azūga™ in-vehicle driving feedback technology, which consists of a pager-sized device plugged into the vehicle's on-board diagnostic port (installed in the teen's car) and a smartphone app (downloaded on the teen's smartphone), will be installed/downloaded. Three types of feedback will be provided to intervention teens: 1) Direct audio feedback from the installed device; 2) Detailed cumulative driving data; and 3) A customized biweekly driving summary report.
Study NCT04317664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Communication
Description: An individualized virtual training in communication strategies about driving safety along with a booster session will be delivered by a traffic safety communication specialist to subjects in the Feedback and Parent Communication Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
Study NCT03431285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Group
Description: Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline infused over 30 min in addition to standard IV hydration.
Study NCT03431285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Group
Description: Patients will receive low dose ketamine 0.3 mg/kg in 100ml N.S. infused over 30 min in addition to standard IV hydration
Study NCT03431285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard IV hydration
Description: IV hydration as per our institutional protocol (Lactated Ringer's or NaCl 0.9% solution will be infused at a rate of 2-3 ml/kg/h)
Study NCT04499391 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Project ECHO
Description: Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation. This differentiates ECHO from traditional learning and facilitates rapid dissemination of medical knowledge and increased capacity to deliver best-practice care.studying innovative approaches.
Study NCT04499391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Project ECHO
Description: Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation. This differentiates ECHO from traditional learning and facilitates rapid dissemination of medical knowledge and increased capacity to deliver best-practice care.studying innovative approaches.
Study NCT00460421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Palifermin will be administered as an IV bolus injection (40, 60 or 80 µg/kg/day)once daily for 3 consecutive days before the start of conditioning regimen and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).
Study NCT00460421 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body irradiation
Study NCT00460421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: High dose etoposide, Cyclophosphamide
Study NCT04205292 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hysteroscopic
Description: Women in the intervention group will receive an inpatient treatment with two-dose of Methotrexate followed by hysteroscopic resection under ultrasound guidance
Study NCT04205292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopic
Description: Women in the intervention group will receive an inpatient treatment with two-dose of Methotrexate followed by hysteroscopic resection under ultrasound guidance
Study NCT03724591 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a high ligation of IMA
Description: total mesorectal excision (TME) for rectal cancer by a high ligation of IMA without preservation of left colic artery
Study NCT03724591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: a low ligation of IMA
Description: total mesorectal excision (TME) for rectal cancer by a low ligation of IMA with preservation of left colic artery
Study NCT00432367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine
Description: Eligible women will be allocated randomly to one of three groups and treated as follows:~Arm 1 (OptiMAL® antigen screening and treatment with SP plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment if her screening test is positive.~Arm 2 (OptiMAL® antigen screening and treatment with AQ+AS plus LLIN) - a woman in this will receive 300mg of AQ and 100mg co-administered two times a day for 3 days if her screening test is positive. The first dose is observed on enrolment day at the ANC.~Arm 3 (SP-IPTp plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment as recommended by national policy.~All enrolled women will be given one long lasting insecticide treated bed net each for use.